IRSN/PSE-SANTÉ-SER/UEM, Fontenay-aux-Roses, France.
IRSN/PSE-SANTÉ-SER/UEM, Fontenay-aux-Roses, France.
Cancer Radiother. 2024 Oct;28(5):463-473. doi: 10.1016/j.canrad.2024.07.001. Epub 2024 Sep 19.
Ultra-high dose rate external beam radiotherapy (UHDR-RT) uses dose rates of several tens to thousands of Gy/s, compared with the dose rate of the order of a few Gy/min for conventional radiotherapy techniques, currently used in clinical practice. The use of such dose rate is likely to improve the therapeutic index by obtaining a radiobiological effect, known as the "FLASH" effect. This would maintain tumor control while enhancing tissues protection. To date, this effect has been achieved using beams of electrons, photons, protons, and heavy ions. However, the conditions required to achieve this "FLASH" effect are not well defined, and raise several questions, particularly with regard to the definition of the prescription, including dose fractionation, irradiated volume and the temporal structure of the pulsed beam. In addition, the dose delivered over a very short period induces technical challenges, particularly in terms of detectors, which must be mastered to guarantee safe clinical implementation. IRSN has carried out an in-depth literature review of the UHDR-RT technique, covering various aspects relating to patient radiation protection: the radiobiological mechanisms associated with the FLASH effect, the used temporal structure of the UHDR beams, accelerators and dose control, the properties of detectors to be used with UHDR beams, planning, clinical implementation, and clinical studies already carried out or in progress.
超高剂量率外照射放疗(UHDR-RT)采用数十至数千 Gy/s 的剂量率,而目前临床实践中使用的常规放疗技术的剂量率约为几 Gy/min。这种剂量率的使用可能会通过获得一种被称为“FLASH”效应的放射生物学效应来提高治疗指数。这将在保持肿瘤控制的同时增强组织保护。迄今为止,这种效应已通过电子、光子、质子和重离子束来实现。然而,实现这种“FLASH”效应的条件尚未得到很好的定义,并提出了几个问题,特别是关于处方的定义,包括剂量分割、照射体积和脉冲束的时间结构。此外,在非常短的时间内给予的剂量会带来技术挑战,特别是在探测器方面,必须掌握这些技术才能保证安全的临床实施。IRSN 对 UHDR-RT 技术进行了深入的文献综述,涵盖了与患者辐射防护相关的各个方面:与 FLASH 效应相关的放射生物学机制、UHDR 束的使用时间结构、加速器和剂量控制、用于 UHDR 束的探测器特性、计划、临床实施以及已经进行或正在进行的临床研究。